Altimmune vs Avalo Therapeutics
ALT and AVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALT and AVTX compare
Avalo Therapeutics is the larger company, worth 1.2 times as much as Altimmune ($456M against $375M).
Avalo Therapeutics scores higher on the StockData Score (8 against 4 for Altimmune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALT | AVTX |
|---|---|---|
| Size and price | ||
| Market cap | $375M | $456M |
| Share price | $1.93 | $8.51 |
| Change, 1 year | −54.7% | −44.1% |
| Change, 5 years | −81.7% | −99.9% |
| Beta (5Y) | 1.10 | 0.88 |
| Employees | 13 | 23 |
| StockData Score | ||
| Total score | 4 | 8 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.8× (better) | 1.0× |
| FCF yield | −20.4% | – |
| Growth | ||
| Revenue growth, 5Y average | −65.3% | −61.2% (better) |
| Profitability | ||
| Return on equity | −28.9% (better) | −33.6% |
| Return on invested capital | −90.4% | – |
| Financial health | ||
| Debt / equity | 0.07 (better) | 0.00 |
| Interest coverage | −28.3× | – |
| Current ratio | 26.78 (better) | 16.63 |
| Altman Z-score | 2.51 | 4.86 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −29.3% | – |
| Shareholder yield | −29.3% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 77.9% | 135% |
| Held by insiders | 0.51% | 0.71% |
| Insider net buying, 12 months | $370K (better) | −$8.3M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 21.8% | 16.7% |
Go deeper
- ALT stock overview
- ALT income statement
- ALT valuation and score
- AVTX stock overview
- AVTX income statement
- AVTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.